Navigation Links
A New President at the Head of the Genethon Laboratory
Date:7/7/2008

Yves Champey Takes Over From Bernard Barataud

EVRY, France, July 7 /PRNewswire/ -- The board of directors at Genethon nominated a new president to head the laboratory created in 1990 by the AFM (French Muscular Dystrophy Association). Thus Yves Champey succeeds Bernard Barataud, who has decided to hand over the reins after heading the laboratory between 1990 and 1995 and then between 1999 and 2008.

Yves Champey is a physician by training. Genethon will benefit from his international experience with responsibility for the development of new drugs within major pharmaceutical companies such as Pfizer and Rhone-Poulenc Rorer. Also, he contributed to the creation of the Drug for Neglected Diseases Initiative (DNDi) - of which he was president from 2003 to 2007. The DNDi is a foundation dedicated to the research and development of new drugs against neglected parasite diseases affecting poor populations. Finally, with Pierre Tambourin, he has been deeply involved in the development of Genopole(R) Evry, and is president of the board of directors of the pre-seed fund G1J Ile-de-France.

"I will be placing all my experience at the service of the AFM and Genethon," declares Yves Champey, "with 3 objectives: successfully implementing the clinical trials programs, reinforcing the position of Genethon as a not-for-profit entity of research and development, and developing the innovative biotherapies for the treatment of rare diseases. My ambition is also to open the way to substantial joint projects with the pharmaceutical and biotechnological industries and to develop those that already exist with public research organisations."

President of the AFM (French Muscular Dystrophy Association) from 1981 to 2001, Bernard Barataud is the father of three children, one of whom died from Duchenne myopathy in 1986 at the age of sixteen. Co-founder of the French Telethon in 1987, he was also the founder of Genethon in 1990 with the Nobel Prize winner Jean Dausset. As early as 1992 Genethon supplied the international scientific community with the first maps of the human genome. This considerably accelerated its deciphering and the discovery of the genes responsible for diseases. It is this progress which has led to innovative therapies based on knowledge of genes, therapies which are now undergoing clinical trials. Eighteen years after its creation, Genethon is today a not-for-profit biotechnology enterprise whose aim is to develop biotherapies for rare genetic diseases. Genethon is the promoter of the first gene therapy trial in humans for gamma-sarcoglycan deficiency. It possesses two clinical batch production units for vectors and is engaged in the development of a pre-industrial scale BMP production site to go onstream in 2010. http://www.genethon.com


'/>"/>
SOURCE Genethon and AFM (French Muscular Dystrophy Association)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IBT Laboratories Names Maureen Loftus President and Chief Operating Officer
2. Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area
3. Battelle Earns 2008 Presidential Green Chemistry Award
4. Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine
5. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
6. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
7. Stereotaxis Appoints Senior Vice President, North America
8. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
9. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
10. Lentigen Appoints Jim Meade as Vice President of Corporate Development
11. Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVaults Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... , ... July 13, 2017 , ... ... and calibration verification test kit has received US FDA 510 (k) clearance for ... human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI ...
(Date:7/13/2017)... TN (PRWEB) , ... July 13, 2017 , ... ... Manufacturer of surgical instruments in Orthopedics, has announced today the completion of a ... majority shareholder to drive organic and external growth. The alliance fuels In’Tech Medical’s ...
(Date:7/13/2017)... ... 13, 2017 , ... Trinity Sterile, Inc., a fast-growing healthcare ... chosen The Copley Consulting Group to implement and deploy the Infor CloudSuite Industrial ... and backend operations to streamline efficiencies to meet the increasing demand for cost-saving ...
(Date:7/12/2017)... CA (PRWEB) , ... July 12, 2017 , ... Dr. ... is the most recent recipient of a Microbiome Impact Grant from uBiome, the leading ... role of the skin microbiome in the transmission of pathogens between elderly people in ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):